Saltar al contenido
Asociación Colombiana de Menopausia · Desde 1994
ASOMENOPAUSIARevista Colombiana de Menopausia · Vol. 19 núm. 4
Vol. 19 núm. 4 / Actualidad inmediata

Actualidad inmediata

Conflicto de interés

Vol. 19 · núm. 4 · 2013Páginas 300–302Descargar artículo (PDF)Ver en la edición impresaCómo citar
En este artículo
  1. Referencias
← Contenido de la edición

No hay conflicto de intereses.

Referencias

  1. Lee JS, Ettinger B, Stanczyk FZ, et al. Comparison of methods to measure low serum estradiol levels in postmenopausal women. J Clin Endocrinol Metab 2006;91: 3791-3797.
  2. Schmidt G, Andersson SB, Nordle O, Johansson CJ, Gunnarsson PO. Release of
  3. beta-oestradiol from a vaginal ring in postmenopausal women: pharmacokinetic evaluation. Gynecol Obstet Invest 1994;38:
  4. 260.
  5. Naessen T, Rodriguez-Macias K. Endometrial thickness and uterine diameter not affected by ultralow doses of 17beta-estradiol in elderly women. Am J Obstet Gynecol 2002;186:944-
  6. 92. Santen RJ, Pinkerton JV, Conaway M, et al. Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause 2002;9: 179-187. 93. Notelovitz M, Funk S, Nanavati N, Mazzeo M. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol 2002; 99:556-562.
  7. Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultralow-dose 10 microg 17beta-estradiol vaginal tablets. Climacteric 2010;13:219-227. 95. Rigg LA, Hermann H, Yen SS. Absorption of estrogens from vaginal creams. N Engl J Med 1978;298:195-197.
  8. Handa VL, Bachus KE, Johnston WW, Robboy SJ, Hammond CB. Vaginal administration of low-dose conjugated estrogens: systemic absorption and effects on the endometrium. Obstet Gynecol 1994; 84:215-218. Stanczyk FZ, Lee JS, Santen RJ. Standardization of steroid hormone assays: why, how, and when? Cancer Epidemiol Biomarkers Prev 2007; 16:1713-1719.
  9. Fischer G, Bradford J. Vulvovaginal candidiasis in postmenopausal women: the role of hormone replacement therapy. J Low Genit Tract Dis 2011;15:263-267.
  10. Dennerstein GJ, Ellis DH. Oestrogen, glycogen and vaginal candidiasis. Aust N Z J Obstet Gynaecol 2001;41:326-328.
  11. Ulrich LS, Naessen T, Elia D, Goldstein JA, Eugster-Hausmann M. Endometrial safety of ultra-low-dose Vagifem 10 microg in postmenopausal women with vaginal atrophy. Climacteric 2010;13:228-237.
  12. Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol 2008;112:1053-1060.
  13. Obiorah I, Jordan VC. 2012 NAMS/PfizerVWulf H. Utian Endowed Lecture. Scientific rational for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality. Menopause 2013;20:372-382.
  14. Mastaglia SR, Bagur A, Royer M, Yankelevich D, Sayegh F, Oliveri B. Effect of endogenous estradiol levels on bone resorption and bone mineral density in healthy postmenopausal women: a prospective study. Climacteric 2009;12:49-58.
  15. Bagur A, Oliveri B, Mautalen C, et al. Low levels of endogenous estradiol protect bone mineral density in young postmenopausal women. Climacteric 2004;7:181-188.
  16. Cicinelli E, Di Naro E, De Ziegler D, et al. Placement of the vaginal 17beta-estradiol tablets in the inner or outer one third of the vagina affects the preferential delivery of 17beta-estradiol toward the uterus or periurethral areas, thereby modifying efficacy and endometrial safety. Am J Obstet Gynecol 2003;189:55-58.
  17. Tourgeman DE, Boostanfar R, Chang L, Lu J, Stanczyk FZ, Paulson RJ. Is there evidence for preferential delivery of ovarian estradiol to the endometrium? Fertil Steril 2001;75: 1156-1158. Fanchin R, De Ziegler D, Bergeron C, Righini C, Torrisi C, Frydman R. Transvaginal administration of progesterone. Obstet Gynecol 1997;90: 396-401.
  18. Ross D, Cooper AJ, Pryse-Davies J, Bergeron C, Whitehead MI. Randomized, double-blind, dose-ranging study of endometrial effects of a vaginal progesterone gel in estrogen-treated postmenopausal women. Am J Obstet Gynecol 1997;177:937-941.
  19. De Ziegler D, Bulletti C, De Monstier B, Ja¨a¨skela¨inen AS. The first uterine pass effect. Ann N Y Acad Sci 1997;828:291-299.
  20. Winneker RC, Harris HA. Progress and prospects in treating postmenopausal vaginal atrophy. Clin Pharmacol Ther 2011;89:129-132.
  21. Biglia N, Peano E, Sgandurra P, et al. Lowdose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol 2010;26:404-412.
  22. Kendall A, Dowsett M, Folkerd E, Smith I. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006;17:584-587.
  23. Col NF, Kim JA, Chleboskwi RT. Menopausal hormone therapy after breast cancer: a metaanalysis and critical appraisal of the evidence. Breast Cancer Res 2005;7:R535-R540.
  24. Le Ray I, Dell,Aniello S, Bonnetain F, Azoulay L, Suissa S. Local estrogen therapy and risk of breast cancer recurrence among hormonetreated patients: a nested case-control study. Breast Cancer Res Treat 2012;135:603-609.
  25. Wills S, Ravipati A, Venuturumilli P, et al. Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract 2012;8:144-148.
  26. Estrace cream [package insert]. Rockaway, NJ: Warner Chilcott, LLC, 2011.
  27. Premarin vaginal cream [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, 2012.
  28. Estragyn vaginal cream [product monograph]. Concord, Ontario, Canada: Triton Pharma Inc, 2010. Estring [package insert]. New York: Pharmacia & Upjohn Co, 2008.
  29. Femring [package insert]. Rockaway, NJ: Warner Chilcott Inc, 2005.
  30. Vagifem [package insert]. Princeton, NJ: Novo Nordisk Inc, 2012.
  31. Bachmann G, Bouchard C, Hoppe D, et al. Efficacy and safety of lowdose regimens of conjugated estrogens cream administered vaginally. Menopause 2009;16:719-727.
  32. American Association of Sexuality Educators, Counselors and Therapists (AASECT) www.aasect.org.
  33. Simon J, Nachtigall L, Ulrich LG, Eugster- Hausmann M, Gut R. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol 2010;116:876-883.
  34. Johnston SL, Farrell SA, Bouchard C, et al; SOGC Joint Committee-Clinical Practice Gynaecology and Urogynaecology. The detection and management of vaginal atrophy. J Obstet Gynaecol Can 2004;26:503-515.
  35. American College of Obstetricians and Gynecologists Women_s Health Care Physicians. Genitourinary tract changes. Obstet Gynecol 2004; 104(suppl 4):56S-61S.
  36. Portman DJ, Bachmann GA, Simon JA; Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013;20:623-630.
  37. Bachmann GA, Komi JO; Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010;17:480-486.
  38. Simon JA, Lin VH, Radovich C, Bachmann GA; The Ospemifene Study Group. Oneyear long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause 2013;20:418-427.
  39. Osphena [package insert]. Florham Park, NJ: Shionogi Inc, 2013.
  40. Wurz GT, Soe LH, Degregorio MW. Ospemifene, vulvovaginal atrophy, and breast cancer [published online ahead of print January 15, 2013]. Maturitas doi 10.1016/j. maturitas. 2012.12.002. Vogel VG, Costantino JP, Wickerham DL, et al.; National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741. Erratum in: JAMA. 2007;298(9):973; JAMA. 2006;296(24):2926.
  41. Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2742-2751. Erratum in: JAMA. 298(9):973.
  42. Davies GC, HusterWJ, Lu Y, Plouffe L, Lakshmanan M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999;93:558-565.
  43. Parsons A, Merritt D, Rosen A, Heath H 3rd, Siddhanti S, Plouffe L Jr; Study Group on the Effects of Raloxifene HCI With Low-Dose Premarin Vaginal Cream. Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy. Obstet Gynecol 2003;101:346-352.
  44. Pinkerton JV, Shifren JL, La Valleur J, Rosen A, Roesinger M, Siddhanti S. Influence of raloxifene on the efficacy of an estradiolreleasing ring for treating vaginal atrophy in postmenopausal women. Menopause 2003;10:
  45. 52.
  46. Stovall DW, Utian QWH, Gass ML, et al. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause 2007;14(3 pt
  47. :510-517.
  48. Fisher B, Costantino JP,Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
  49. Chollet JA. Update on alternative therapies for vulvovaginal atrophy. Patient Prefer Adherence 2011:5:533-536.
  50. Portman D, Moffett A, Kerber I, Drosman S, Somayaji V, Lee A. Vaginal effects of lasofoxifene and raloxifene: preliminary evidence suggests lasofoxifene, but not raloxifene, improves indices of vaginal health [abstract]. Menopause 2004;11:675. Abstract P-87.
  51. LaCroix AZ, Powles T, Osborne CK, et al.; PEARL Investigators. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst 2010;102:1706-1715.
  52. Bachmann G, Gass M, Kagan R, Moffett A, Barcomb L, Symons J. Lasofoxifene (LASO), a next generation selective estrogen response modulator (SERM) improves dyspareunia in postmenopausal women with vaginal atrophy (VA) [abstract]. Menopause 2005;12:238. Menopause, Vol. 20, No. 9, 2013 901 NAMS POSITION STATEMENT
  53. Lobo RA, Pinkerton JV, Gass ML, et al. Evaluation of bazedoxifene/ conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009;92:1025-1038.
  54. Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo- and activecontrolled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 2010;17:281-289. 145. Labrie F, Archer D, Bouchard C, et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause 2009;16:907-
  55. Labrie F, Archer D, Bouchard C, et al. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecol Endocrinol 2010;26:524-532.
  56. Chi CC, Kirtschig G, Baldo M, Brackenbury F, Lewis F, Wojnarowska F. Topical interventions for genital lichen sclerosus. Cochrane Database Syst Rev. 2011;7:CD008240.
  57. Witherby S, Johnson J, Demers L, et al. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Oncologist 2011;16:424-431.
  58. Nappi RE, Davis SR. The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI. Climacteric 2012;15:267-274.

Cómo citar este artículo

Vancouver

Conflicto de interés. Rev Col Menop. 2013;19(4):300-302.

APA 7

Conflicto de interés. (2013). Revista Colombiana de Menopausia, 19(4), 300–302.

Descargar este artículo (PDF)Descargar cita (RIS)

El archivo RIS se importa en Zotero, Mendeley o EndNote. Revisa los nombres de los autores: la cita se arma automáticamente a partir del artículo.